Cullinan Therapeutics, Inc. (CGEM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.09-0.32%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CGEM
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue clinical development of CLN-978 in treatment-refractory SLE, RA, and Sjögren’s disease with focus on safety, B cell depletion, and clinical remission data.
Stated as a priority in 3 distinct disclosures including 2026-Q1 and 2026-Q2. Management highlights clinical remissions and deep B cell depletion in refractory SLE and RA patients treated with CLN-978, with multi-dose regimen data expected in Q3 and Q4 2026. The trajectory shows active clinical development progress with emerging efficacy and safety data supporting advancement.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“New multi-dose data in Phase 1 OUTRACE RA demonstrate robust efficacy of CLN-978 in refractory patients.”
“CLN-978 shows promise in autoimmune diseases with initial clinical data to be presented in 2026.”
Develop velinotamig for treatment-refractory autoimmune diseases driven by plasma cells, with clinical data expected in late 2026 and planned global trials.
Stated in 2 disclosures including 2026-Q1 and 2026-Q2. Management reports early clinical efficacy with complete renal responses in refractory SLE patients and plans to share additional data in Q4 2026. The development trajectory is active with ongoing clinical evaluation and planned expansion.
“Initial velinotamig data show promising clinical activity including complete renal responses in lupus nephritis.”
“Velinotamig is in Phase 1 study in China with plans to accelerate global clinical development.”
Advance CLN-049 clinical program in AML and MDS with dose escalation updates and planned Phase 2 registrational trial initiation in late 2026.
Stated in 2 disclosures including 2026-Q1 and 2026-Q2. Management reports ongoing dose escalation to establish RP2D for CLN-049 with plans to initiate a registrational Phase 2 trial in Q4 2026. The program is progressing with clinical milestones on track.
“Plan to initiate Phase 1/2 combination study in untreated AML patients in Q4 2026.”
“Dose level expansion continues to determine recommended Phase 2 dose for CLN-049 by Q4 2026.”
Manage cash resources prudently to ensure operational runway extends into fiscal year 2029 under current operating plan.
Stated in 2 disclosures including 2025-Q3 and 2026-Q1. Management expects cash resources to provide operational runway into 2029. Financials show cash and investments of $393.3 million as of 2026-Q1. The trajectory is consistent with maintaining sufficient liquidity for planned operations.
“Cullinan expects its cash resources to provide runway into 2029 under its current operating plan.”
“Company expects cash resources to provide runway into 2029 based on new operating plan.”
Collaborate with Taiho Oncology to seek FDA approval for zipalertinib plus chemotherapy in first-line treatment of EGFR exon 20 insertion NSCLC.
Newly stated in 2026-Q2. Management announced positive topline Phase 3 interim results for zipalertinib plus chemotherapy in first-line NSCLC and plans to pursue U.S. regulatory approval. This is a recent development with initial regulatory engagement underway.
“Plan to pursue U.S. regulatory approval for zipalertinib in combination with chemotherapy in first-line NSCLC.”
Over the trailing year it converted 0.90x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.